Is AOD-9604 Legal in Oregon? How Women Can Access It Safely

What Is AOD-9604 and Why Are Oregon Women Asking About It?

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically amino acids 176-191 of the hGH C-terminal region. Researchers originally developed it in Australia at Monash University in the 1990s with the hope it could replicate hGH's fat-burning properties without raising IGF-1 levels or causing blood sugar problems.

The drug never made it to market. Its developer, Metabolic Pharmaceuticals, ran phase 2 and phase 3 trials in the early 2000s. The largest trial, published in 2001, enrolled 300 adults with obesity and showed modest but statistically significant weight loss over 12 weeks at doses of 1 mg/day orally, though results at injectable doses were more variable 1. The compound received GRAS (generally recognized as safe) status from the FDA in 2014 as a food ingredient at low doses, but that designation does not translate to approval as a drug or a valid compounded medication.

Women in Oregon are searching for AOD-9604 largely because GLP-1 receptor agonists like semaglutide and tirzepatide are still subject to supply shortages and high out-of-pocket costs, and peptide therapy has grown rapidly as an alternative in wellness and functional medicine spaces. That demand is real. So is the regulatory uncertainty.

How AOD-9604 Differs From GLP-1 Medications

GLP-1 agonists like semaglutide work by mimicking a gut hormone that slows gastric emptying, reduces appetite, and improves insulin sensitivity. AOD-9604 operates through a completely different mechanism: it is thought to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) through a pathway independent of the GH receptor, possibly via beta-3 adrenergic receptors 1. This distinction matters for women with insulin resistance or PCOS, where the insulin-sensitizing effects of GLP-1 drugs may be more directly relevant than lipolysis alone.

GLP-1 drugs have FDA approval, established dosing protocols, and a growing body of cardiovascular outcome data from trials like SUSTAIN-6 and SELECT. AOD-9604 has none of these. That gap is not a minor regulatory technicality; it is a clinically meaningful difference in what your prescriber can tell you with confidence about long-term safety.

The Federal Legal Framework: Where AOD-9604 Actually Stands

This is where the answer becomes uncomfortable. AOD-9604 is not FDA-approved as a drug. It cannot be legally sold as a pharmaceutical product without a prescription from a licensed provider plus dispensing by a pharmacy operating under specific compounding rules.

The FDA Bulk Substances List

FDA regulations under Section 503A of the Federal Food, Drug, and Cosmetic Act govern what compounding pharmacies serving individual patients can and cannot prepare. In 2023, the FDA released a draft list of bulk drug substances that are NOT eligible for compounding because they have not been nominated, have been found to lack sufficient evidence of clinical use, or raise safety concerns 2. AOD-9604 appeared on this list.

The FDA's 2023 draft guidance stated that AOD-9604 was nominated for the 503A bulk substances list but was placed in Category 2, meaning the agency found insufficient clinical evidence to support its compounding for patient use 2. A Category 2 designation does not automatically make all compounding instantly illegal at the moment of publication (the FDA issues these as proposed rules that go through comment periods), but it is a strong regulatory signal that compounding AOD-9604 is legally precarious and may be prohibited as the rule is finalized.

Think of the federal legal status in three tiers:

• Tier 1 (Clear legal): FDA-approved drugs dispensed by a licensed pharmacy with a valid prescription.
• Tier 2 (Gray zone): Bulk substances on the 503A "may compound" list, prepared by a 503A or 503B pharmacy with a patient-specific prescription. Semaglutide was here during the shortage designation period.
• Tier 3 (Legally precarious): Bulk substances on the 503A "do not compound" draft list or Category 2 list. AOD-9604 is currently here.

Buying AOD-9604 labeled "for research use only" from an online peptide vendor does not create a legal or medical workaround. Those products are not regulated for purity, potency, or sterility. Injecting a research-grade peptide purchased without a prescription carries real infection and contamination risk.

What the FDA's GRAS Designation Does and Does Not Mean

Some peptide providers market AOD-9604 by pointing to its 2014 GRAS designation from the FDA. That designation covers AOD-9604 as a food additive at very low oral doses, not as an injectable drug at weight-loss doses 3. A GRAS notice does not authorize medical use, prescribing, or injection. These are legally distinct categories.

Oregon State Law: What the Board of Pharmacy Says

Oregon does not have a separate state statute that specifically names AOD-9604 or overrides federal compounding law. The Oregon Board of Pharmacy licenses pharmacies operating within the state and requires them to comply with federal USP standards and the federal 503A/503B compounding framework 4.

Oregon 503A Compounding Pharmacies

A 503A pharmacy in Oregon can prepare a compounded drug for an individual patient only if:

1. A licensed prescriber writes a patient-specific prescription.
2. The drug is on the FDA's approved bulk substances list or meets the criteria for compounding from an FDA-approved drug product.
3. The compounded preparation is not essentially a copy of an FDA-approved commercial drug.

Given AOD-9604's Category 2 placement, an Oregon 503A pharmacy that compounds AOD-9604 is operating in direct tension with the FDA's current regulatory position. Some pharmacies may still prepare it while the final rule is pending. Others have stopped. This is the core of the legal ambiguity you will encounter if you start calling compounding pharmacies in Portland, Eugene, or Bend.

Oregon 503B Outsourcing Facilities

503B outsourcing facilities produce larger batches of compounded drugs for use in clinical settings. The restrictions on bulk substances are, if anything, more stringent for 503B facilities than for 503A pharmacies, and no FDA-registered 503B facility currently lists AOD-9604 as a product on its active formulary as of mid-2025.

Oregon Medical Practice Act

Oregon's Medical Practice Act allows licensed physicians, nurse practitioners, and physician assistants to prescribe compounded medications within the scope of their practice. However, a valid prescription for a substance that a pharmacy cannot legally compound does not solve the underlying problem. The prescriber obligation and the pharmacy obligation are separate, and both must be met for a legal supply chain to exist.

How Oregon Women Are Currently Accessing AOD-9604

The practical reality is that some Oregon women are obtaining AOD-9604 through three routes, each with different risk profiles.

Route 1: Licensed Telehealth or Functional Medicine Clinician Plus a Compounding Pharmacy

This is the closest thing to a legal path that exists right now. A licensed Oregon prescriber writes a patient-specific prescription for AOD-9604. A 503A compounding pharmacy in Oregon (or a licensed out-of-state pharmacy that ships to Oregon) fills the prescription. This route requires a real medical evaluation, a documented clinical rationale in the chart, and a pharmacy willing to compound AOD-9604 under current regulatory uncertainty.

If you pursue this route, ask your prescriber directly: "Is the pharmacy you use currently operating in compliance with the FDA's 2023 draft bulk substances guidance?" A clinician who cannot answer that question is not fully informed about the regulatory environment.

Route 2: Research Peptide Vendors (Not Recommended)

Dozens of online vendors sell AOD-9604 labeled "not for human use" or "research chemical only." These products are not FDA-regulated for sterility, purity, or potency. A 2021 analysis of peptides purchased from online vendors found that 5 a significant proportion contained incorrect concentrations or detectable contaminants. Injecting an unregulated product purchased this way carries risk of local injection-site infection, abscess, and systemic contamination. There is no legal prescription, no pharmacy oversight, and no clinician involved.

Route 3: Medical Spa or Wellness Clinic Dispensing

Some Oregon medical spas and wellness clinics offer AOD-9604 as part of a "peptide protocol." In many cases, these clinics are sourcing from compounding pharmacies and have a licensed prescriber on staff. In other cases, the oversight is thinner. Before you accept an injection at any wellness clinic, ask to see the prescriber's license, the pharmacy's name and 503A registration, and the certificate of analysis (COA) for the specific batch of medication.

Who AOD-9604 May Be Right For (and Who It Is Not Right For)

Because AOD-9604 is not FDA-approved, there are no official clinical indications. Based on its mechanism and the available trial data, the women most likely to be evaluated for it by a knowledgeable clinician fall into a narrow category.

Women Who May Be Considered

• Women with a BMI >27 with weight-related comorbidities who have not responded adequately to lifestyle intervention and who are not candidates for GLP-1 therapy (for example, due to a personal or family history of medullary thyroid carcinoma, pancreatitis, or intractable GI side effects).
• Women in reproductive years with PCOS and central adiposity, where reducing fat mass may improve hormonal balance and insulin sensitivity, though no trial has specifically studied AOD-9604 in women with PCOS.
• Perimenopausal and postmenopausal women experiencing the metabolic shift toward central fat redistribution. Estrogen loss drives a measurable increase in visceral adiposity 6, and some clinicians in the functional medicine space are exploring AOD-9604 as an adjunct to hormone therapy in this population. There is no published trial to support or refute this use.

Women Who Should Not Use AOD-9604

• Anyone who is pregnant, trying to conceive, or postpartum and breastfeeding. See the dedicated section below.
• Women with active cancer or a history of hormone-sensitive cancer, given AOD-9604's structural relationship to hGH. While AOD-9604 is believed not to raise IGF-1 levels, the long-term oncologic safety data simply does not exist.
• Women with uncontrolled thyroid disease. Growth hormone fragments can interact with thyroid hormone metabolism; your thyroid levels should be stable and monitored if you pursue any peptide therapy.
• Women currently taking insulin or sulfonylureas, without close glucose monitoring. The clinical trial data suggested AOD-9604 has minimal effect on insulin levels 1, but that data is from oral dosing, not injectable dosing, and extrapolating it to a woman on diabetes medications requires prescriber judgment.

Pregnancy, Lactation, and Contraception: Do Not Use AOD-9604

AOD-9604 is contraindicated in pregnancy. Full stop.

There are no human data on AOD-9604 use during pregnancy. There are no animal reproductive toxicology studies in the published literature that have been independently verified. Because AOD-9604 is a fragment of human growth hormone, and because growth hormone signaling plays a documented role in placental development and fetal growth 7, the theoretical concern for fetal harm is real.

The FDA has not assigned AOD-9604 a formal pregnancy category (those categories were retired in 2015 for approved drugs and replaced with labeling narratives). For an unapproved compounded substance, no pregnancy labeling exists at all. In the absence of safety data, the standard clinical position is: do not use.

Lactation

There are no data on AOD-9604 transfer into human breast milk, infant dose, or infant outcomes. Given that it is a peptide (it would likely be degraded in the infant's GI tract), transfer may be low, but "may be low" is not a basis for recommending use during lactation. The LactMed database does not contain an entry for AOD-9604 8. Avoid use while breastfeeding.

Contraception

If you are a woman of reproductive age using AOD-9604 through any access route, use reliable contraception throughout treatment and for at least one full menstrual cycle after stopping, until more reproductive safety data exist. Discuss this explicitly with your prescriber at the time the prescription is written. A prescriber who does not bring up contraception when prescribing AOD-9604 to a woman of reproductive potential is missing a basic step.

Sex-Specific Physiology: What Women Need to Know That the Trials Did Not Cover

The clinical trials of AOD-9604 conducted by Metabolic Pharmaceuticals in the early 2000s enrolled mixed-sex populations, and none of the published analyses reported results stratified by sex 1. This is a meaningful evidence gap. Women have been historically underrepresented in metabolic and obesity trials, and the data that exists for AOD-9604 cannot be assumed to apply equally to women.

The Menstrual Cycle and Fat Metabolism

Fat metabolism in women changes across the menstrual cycle. During the luteal phase, progesterone increases fat oxidation. During the follicular phase, estrogen enhances lipid mobilization in some tissues. Whether AOD-9604's lipolytic effect is amplified, blunted, or unaffected by these hormonal shifts is unknown. No trial has measured this.

Perimenopause and Postmenopause

The metabolic shift at menopause is well documented. Women gain an average of 1.5 kg per year during the menopausal transition 6, and visceral fat accumulates preferentially. Estrogen therapy has been shown in randomized trials to attenuate this visceral fat gain 9. AOD-9604's potential interaction with estrogen therapy in this population has never been studied. Prescribers who combine these treatments are doing so without a safety or efficacy evidence base specific to postmenopausal women.

Female-Pattern Metabolic Disease and PCOS

PCOS affects approximately 10 6-12% of women of reproductive age and is characterized by insulin resistance, hyperandrogenism, and difficulty with fat loss. GLP-1 medications have demonstrated benefit in PCOS in randomized trials, including improvements in menstrual regularity and androgen levels. AOD-9604 has no published data in women with PCOS. Any clinician suggesting it as a PCOS treatment is extrapolating from a mechanism, not from evidence.

What to Ask Your Oregon Prescriber Before Starting

If you are an Oregon woman considering AOD-9604 through a telehealth platform or a local clinician, bring these questions to your first appointment.

• Can you confirm the compounding pharmacy you use is 503A-licensed and has a current COA for AOD-9604 showing sterility and potency testing?
• How do you justify prescribing AOD-9604 given the FDA's 2023 Category 2 draft designation?
• What monitoring will you do? At minimum, ask about thyroid panel, fasting glucose, and a baseline lipid panel.
• What is the stopping criteria? Weight-loss peptides should have a defined endpoint and reassessment schedule, not an indefinite open prescription.
• Is my contraception method reliable for the duration of this treatment?

A prescriber who cannot answer these questions clearly, or who dismisses them as unnecessary, is not operating at the standard of care you deserve.

The Evidence Gap: What Is Directly Studied Versus Extrapolated

Here is an honest accounting of what is known and what is not for AOD-9604 in women.

| Claim | Evidence level | Women-specific data? | |---|---|---| | AOD-9604 reduces fat mass at 1 mg/day orally | Phase 2/3 trials, 2001 1 | Not reported by sex | | AOD-9604 does not raise IGF-1 or fasting glucose | Phase 2/3 trials, 2001 1 | Not reported by sex | | Injectable AOD-9604 is effective for fat loss | No strong human RCT | No | | AOD-9604 is safe in pregnancy | No human data at all | No | | AOD-9604 benefits women with PCOS | No published trial | No | | AOD-9604 is safe long-term | No long-term human data (>12 weeks RCT) | No |

This table is not meant to discourage inquiry. Extrapolation from mechanism to clinical use happens across all of medicine. But you deserve to know exactly where the evidence ends and where your clinician's judgment begins.